AIML Continues to Streamline for the Future and Moves Beyond Tech2Heal
AI/ML Innovations Inc. (AIML) has announced its strategic exit from Tech2Heal SAS (T2H) through a formal agreement dated March 21, 2025. This decision follows a previously reported impairment loss of $1,510,668 from their T2H investment in October 2024.
Under the exit agreement, AIML will relinquish its 11.11% equity position in T2H, board seat rights, and AI RX Inc.'s exclusive North American product rights. In exchange, T2H will return 1,500,000 AIML common shares for cancellation and surrender its 30% equity in AI RX Inc. Additionally, T2H's CEO Fabrice Pakin will step down from both AIML and AI RX Inc.'s boards.
The company will now focus on commercializing its core holdings: NeuralCloud Solutions Inc., Health Gauge Inc. (95.2% owned), and Quantum Sciences . This restructuring aims to optimize the utilization of AIML's human, financial, and technological resources while remaining open to future collaborations with T2H.
AI/ML Innovations Inc. (AIML) ha annunciato la sua uscita strategica da Tech2Heal SAS (T2H) attraverso un accordo formale datato 21 marzo 2025. Questa decisione segue una perdita di valore riportata di $1,510,668 dal loro investimento in T2H nell'ottobre 2024.
Secondo l'accordo di uscita, AIML rinuncerà alla sua partecipazione azionaria dell'11,11% in T2H, ai diritti di seggi nel consiglio e ai diritti esclusivi di prodotto per il Nord America di AI RX Inc. In cambio, T2H restituirà 1.500.000 azioni ordinarie AIML per la cancellazione e rinuncerà alla sua partecipazione del 30% in AI RX Inc. Inoltre, il CEO di T2H, Fabrice Pakin, si dimetterà dai consigli di amministrazione sia di AIML che di AI RX Inc.
L'azienda si concentrerà ora sulla commercializzazione delle sue partecipazioni principali: NeuralCloud Solutions Inc., Health Gauge Inc. (95,2% di proprietà) e Quantum Sciences. Questa ristrutturazione mira a ottimizzare l'utilizzo delle risorse umane, finanziarie e tecnologiche di AIML, rimanendo aperta a future collaborazioni con T2H.
AI/ML Innovations Inc. (AIML) ha anunciado su salida estratégica de Tech2Heal SAS (T2H) a través de un acuerdo formal fechado el 21 de marzo de 2025. Esta decisión sigue a una pérdida de deterioro previamente reportada de $1,510,668 de su inversión en T2H en octubre de 2024.
Bajo el acuerdo de salida, AIML renunciará a su participación accionaria del 11,11% en T2H, a los derechos de asiento en la junta y a los derechos exclusivos de producto de AI RX Inc. para América del Norte. A cambio, T2H devolverá 1,500,000 acciones ordinarias de AIML para su cancelación y renunciará a su participación del 30% en AI RX Inc. Además, el CEO de T2H, Fabrice Pakin, renunciará a los consejos de administración de AIML y AI RX Inc.
La empresa se centrará ahora en comercializar sus participaciones principales: NeuralCloud Solutions Inc., Health Gauge Inc. (95,2% de propiedad) y Quantum Sciences. Esta reestructuración tiene como objetivo optimizar la utilización de los recursos humanos, financieros y tecnológicos de AIML, manteniéndose abierta a futuras colaboraciones con T2H.
AI/ML Innovations Inc. (AIML)는 2025년 3월 21일자로 Tech2Heal SAS (T2H)에서 전략적으로 철수하기로 발표했습니다. 이 결정은 2024년 10월 T2H 투자에서 $1,510,668의 손실을 보고한 데 따른 것입니다.
철수 계약에 따라 AIML은 T2H에서 11.11%의 지분, 이사회 좌석 권리 및 AI RX Inc.의 북미 독점 제품 권리를 포기합니다. 그 대가로 T2H는 AIML의 보통주 1,500,000주를 취소를 위해 반환하고 AI RX Inc.의 30% 지분을 포기합니다. 또한 T2H의 CEO인 Fabrice Pakin은 AIML과 AI RX Inc.의 이사회에서 사임할 것입니다.
회사는 이제 NeuralCloud Solutions Inc., Health Gauge Inc. (95.2% 소유) 및 Quantum Sciences와 같은 핵심 보유 자산의 상용화에 집중할 것입니다. 이번 구조조정은 AIML의 인적, 재무 및 기술 자원의 활용을 최적화하는 것을 목표로 하며, T2H와의 향후 협력 가능성에도 열려 있습니다.
AI/ML Innovations Inc. (AIML) a annoncé sa sortie stratégique de Tech2Heal SAS (T2H) par le biais d'un accord formel daté du 21 mars 2025. Cette décision fait suite à une perte de valeur précédemment signalée de 1 510 668 $ concernant leur investissement dans T2H en octobre 2024.
Selon l'accord de sortie, AIML renoncera à sa participation de 11,11 % dans T2H, à ses droits de siège au conseil d'administration et aux droits exclusifs de produit d'AI RX Inc. pour l'Amérique du Nord. En échange, T2H restituera 1 500 000 actions ordinaires AIML pour annulation et renoncera à sa participation de 30 % dans AI RX Inc. De plus, le PDG de T2H, Fabrice Pakin, démissionnera des conseils d'administration d'AIML et d'AI RX Inc.
L'entreprise se concentrera désormais sur la commercialisation de ses participations clés : NeuralCloud Solutions Inc., Health Gauge Inc. (95,2 % détenu) et Quantum Sciences. Cette restructuration vise à optimiser l'utilisation des ressources humaines, financières et technologiques d'AIML tout en restant ouverte à de futures collaborations avec T2H.
AI/ML Innovations Inc. (AIML) hat seinen strategischen Ausstieg aus Tech2Heal SAS (T2H) durch einen formellen Vertrag vom 21. März 2025 angekündigt. Diese Entscheidung folgt einem zuvor berichteten Wertverlust von $1,510,668 aus ihrer T2H-Investition im Oktober 2024.
Im Rahmen des Ausstiegs wird AIML seine 11,11%ige Beteiligung an T2H, die Rechte auf einen Platz im Vorstand und die exklusiven Produktrechte von AI RX Inc. für Nordamerika aufgeben. Im Gegenzug wird T2H 1.500.000 AIML-Stammaktien zur Stornierung zurückgeben und seine 30%ige Beteiligung an AI RX Inc. aufgeben. Darüber hinaus wird der CEO von T2H, Fabrice Pakin, von den Vorständen von AIML und AI RX Inc. zurücktreten.
Das Unternehmen wird sich nun auf die Kommerzialisierung seiner Kernbeteiligungen konzentrieren: NeuralCloud Solutions Inc., Health Gauge Inc. (95,2% im Besitz) und Quantum Sciences. Diese Umstrukturierung zielt darauf ab, die Nutzung der menschlichen, finanziellen und technologischen Ressourcen von AIML zu optimieren und gleichzeitig offen für zukünftige Kooperationen mit T2H zu bleiben.
- Recovery of 1.5M common shares through cancellation
- Elimination of future capital requirements for Tech2Heal investment
- Streamlined focus on core profitable assets
- $1,510,668 impairment loss on Tech2Heal investment
- Loss of North American product rights and market presence
- Reduction in portfolio diversification
AIML Sharpens Focus with Strategic Exit from Tech2Heal
Aligning Resources for Commercialization and Core Portfolio Growth
Transition Positions AIML to Prioritize Commercial Execution While Remaining Open to Future Collaboration
VANCOUVER, BC / ACCESS Newswire / March 21, 2025 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) is pleased to announce the execution of a formal exit agreement dated March 21, 2025 (the "Agreement") with Tech2Heal SAS ("T2H"), a France-based digital health company in which AIML previously held a minority interest.
On October 10, 2024, AIML reported an impairment loss of
Per the Agreement, AIML will relinquish: 1) its
Paul Duffy, CEO and Chairman of AIML, stated: "AIML remains committed to advancing digital health innovations that leverage artificial intelligence and machine learning. Looking ahead, this decision provides a clean transition and plenty of room for collaboration between our two organizations, particular with our ECG signal algorithm, while we maintain our focus on high-impact opportunities within our core portfolio. We appreciate T2H's contributions and look forward to potential collaborations in the future"
For more information about AIML:
For detailed information please see AIML's website or the Company's filed documents at www.sedarplus.ca.
For further information, contact: Blake Fallis at (778) 405-0882 or info@aiml-innovations.com.
About AI/ML Innovations Inc. https://aiml-innovations.com/
AIML Innovations Inc. has realigned its business operations to capitalize on the burgeoning fields of artificial intelligence: (AI) and machine learning (ML), with an initial investment focus on emerging digital health and wellbeing companies that leverage AI, ML, cloud computing and digital platforms to drive transformative healthcare management solutions and precision support delivery across the health continuum. Through its
On behalf of the Board of Directors:
Paul Duffy, Executive Chairman
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Statements - Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties, including with respect to the completion of the transactions proposed by the Agreement. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of AIML, including the timing and nature of all closing deliverables and whether the transactions contemplated by the Agreement will be completed as currently proposed or at all. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements.
SOURCE: AI/ML Innovations, Inc.
View the original press release on ACCESS Newswire